International Journal of Endocrinology and Metabolism
Research Institute for Endocrine Sciences
OpenCitations
Works that cite this article, indexed by OpenCitations.
ADD2Dia: Real-World Clinical Effectiveness of Adding a Sodium-Glucose Cotransporter 2 Inhibitor to Gliclazide-Based Therapy in Type 2 Diabetes
Advances in Therapy 42(12) (2025)
Rodrigo O. Moreira; Nemencio A. Nicodemus; Abdurrahman Comlekci; Miao Yu; Mussa H. Almalki
Incident infection risks depending on oral antidiabetic exposure in insulin-treated type 2 diabetes patients
Scientific Reports 13(1) (2023)
Sanghwa Park; Jiseon Jeong; Yunna Woo; Yeo Jin Choi; Sooyoung Shin
Metabolic effects of pioglitazone and sodium-glucose cotransporter 2 inhibitors in familial partial lipodystrophy
Acta Diabetologica 63(3) (2025)
Utku Soyaltin; Ilgin Y. Simsir; Baris Akinci
Метаболічні ефекти інгібіторів натрійзалежного котранспортера глюкози 2 типу
Clinical Endocrinology and Endocrine Surgery(4) (2022)
А. В. Кедик; О. О. Куцин
SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
Scientific Reports 15(1) (2025)
Birdie Huang; Chieh-Li Yen; Chao-Yi Wu; Chung-Ying Tsai; Jia-Jin Chen; Ching-Chung Hsiao; Yung-Chang Chen; I-Chang Hsieh; Huang-Yu Yang
Fournier’s Gangrene in an HIV-Positive Patient Using a Sodium-Glucose Cotransporter-2 Inhibitor: A Case Report
Journal of Wound Management and Research 21(1) (2025)
Woohyuk Yoon; Joon Ho Lee
Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus
Frontiers in Endocrinology 16 (2025)
Haoyi Yang; Yuwen Zhang; Yuxin Hong; Yuan Wei; Yuning Zhu; Lei Huang; Yuanxun Yang; Runbin Sun; Juan Li
Early Use of SGLT2 Inhibitors in Heart Failure With Preserved Ejection Fraction: Quantitative Analysis of Cardiac Biomarkers, Renal Function, and In-Hospital Mortality
Revista de Gestão Social e Ambiental 19(2) (2025)
Luiz Francisco de Souza Neto; Camila Maria Bertão Carvalho; Laura Emilly de Moura Bezerra; Luciano Victor Vasconcelos Saldanha; Artur Freire Brito; Kerolaine Silva Fonseca; Fernando Paniago Santini; Dionéa Ferreira Ayres Viana; Hildo Santiago Reis de Aguiar; Amanda Pinheiro Oliveira; Mariana Mota Benevides de Oliveira; Nelso Gabriel Lippo Turmina; Luis Guilherme Rodrigues de Almeida Moutinho; Rebeca Carvalho Wanderley de Lima Lôbo; Layanna Pessoa Marçal de Oliveira; Raíssa Maria Silvestre Santos; Aurélia Lorena Toscano de Medeiros Borges de Méllo; Levy Alves Pinto Loureiro; Dulce Cerqueira Ferreira Cavalcanti; Ana Clara Onofre Brito Chaves; José Mateus da Silva Bomfim; Ellen Pereira Areal; Maria Eduarda Morales Rodrigues; Rodrigo Porcionato; Joseane Oliveira Braga Nascimento; Harley Davidson Rocha de Lima; Giovana Mendelski Pereira
Analysis of Prescription Patterns of Antidiabetic Medication in a County From North-Western Romania
Internal Medicine 22(1) (2025)
Cosmin Mihai Vesa
Do we have enough evidence to support the use of SGLT2 inhibitors for MACE reduction in patients with advance kidney disease?
European Journal of Internal Medicine 70 (2019)
Rajkumar Doshi; Zahara Meghji; Ashish Kumar; Mariam Shariff; Devina Adalja
Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK
Diabetes Therapy 11(9) (2020)
Mafalda Ramos; Michael H. Cummings; Anastasia Ustyugova; Syed I. Raza; Shamika U. de Silva; Mark Lamotte
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
Diabetes Therapy 11(2) (2019)
David M. Williams; Asif Nawaz; Marc Evans
The Evaluation of Cardiovascular Risk in Diabetic Patients
European Pharmaceutical Journal 69(1) (2022)
S. Kosirova; D. Rubintova; J. Lacka; J. Klimas; T. Foltanova; I. Tumova
Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination
touchREVIEWS in Endocrinology 17(1) (2021)
Johan H Jendle; Francisco J Ampudia-Blasco; Martin Füchtenbusch; Paolo Pozzilli
Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination
European Endocrinology 1(1) (2021)
Johan H Jendle; Francisco J Ampudia-Blasco; Martin Füchtenbusch; Paolo Pozzilli
Sodium-glucose Co-transporter-2 inhibitors (SGLT2I): A class of drugs with promising cardiorenal protective effects beyond glycemic control
Annals of Medicine & Surgery 81 (2022)
Abdullah Zaawari; Aaminah Najmus Sahar
The sodium–glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice
FEBS Open Bio 10(12) (2020)
Zi Li; Maki Murakoshi; Saki Ichikawa; Takeo Koshida; Eri Adachi; Chigure Suzuki; Seiji Ueda; Tomohito Gohda; Yusuke Suzuki
Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes
Kidney International Reports 6(8) (2021)
Hongyan Liu; Vikas S. Sridhar; Leif Erik Lovblom; Yuliya Lytvyn; Dylan Burger; Kevin Burns; Davor Brinc; Patrick R. Lawler; David Z.I. Cherney
Diastolic dysfunction and impaired cardiac output reserve in dysmetabolic nonhuman primate with proteinuria
Journal of Diabetes and its Complications 35(4) (2021)
Johannes Wikstrom; Yongqiang Liu; Carl Whatling; Li-ming Gan; Peter Konings; Binchen Mao; Chao Zhang; Yanqin Ji; Yong-Fu Xiao; Yixin Wang
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
International Journal of Molecular Sciences 23(7) (2022)
Teresa Salvatore; Raffaele Galiero; Alfredo Caturano; Luca Rinaldi; Anna Di Martino; Gaetana Albanese; Jessica Di Salvo; Raffaella Epifani; Raffaele Marfella; Giovanni Docimo; Miriam Lettieri; Celestino Sardu; Ferdinando Carlo Sasso
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
Clinical and Molecular Hepatology 27(2) (2021)
Karn Wijarnpreecha; Elizabeth S. Aby; Aijaz Ahmed; Donghee Kim
Renoprotective mechanisms of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease
Journal of Cellular Physiology 237(2) (2021)
Sreenithya Ravindran; Shankar Munusamy
A practical review of diabetes mellitus type 2 treatment in primary care
Romanian Journal of Internal Medicine 60(1) (2022)
Justin T. Call; Pedro Cortés; Dana M. Harris
A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Volume 14 (2021)
Lianglan Shen; Hongli Yang; Xingxing Fang; Huaxing Huang; Wubin Yao; Dongmei Chen; Yan Shen
Sodium–glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients
Journal of Diabetes Investigation 12(1) (2020)
Atsunori Kashiwagi; Shinchi Araki; Hiroshi Maegawa
Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
Theranostics 11(9) (2021)
Zhenghong Liu; Xiaoxuan Ma; Iqra Ilyas; Xueying Zheng; Sihui Luo; Peter J. Little; Danielle Kamato; Amirhossein Sahebkar; Weiming Wu; Jianping Weng; Suowen Xu
Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy
World Journal of Cardiology 13(12) (2021)
Mouhamed Nashawi; Mahmoud S Ahmed; Toka Amin; Mujahed Abualfoul; Robert Chilton
Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes
BMC Nephrology 21(1) (2020)
Gregory A. Nichols; Anouk Déruaz-Luyet; Kimberly G. Brodovicz; Teresa M. Kimes; A. Gabriela Rosales; Sibylle J. Hauske
Prevalence of Bacterial Urinary Tract Infection Among Patients With Type 2 Diabetes Mellitus on Sodium-Glucose Cotransporter-2 Inhibitors: A Prospective Real-World Setting Study
Journal of the ASEAN Federation of Endocrine Societies 37(2) (2022)
Pankaj Ferwani; Assim Maldar; Nishitkumar Shah; Phulrenu Shah; Manoj Chadha
Associations between second‐line glucose‐lowering combination therapies with metformin and HbA1c , body weight, quality of life, hypoglycaemic events and glucose‐lowering treatment intensification: The DISCOVER study
Diabetes, Obesity and Metabolism 23(8) (2021)
Kamlesh Khunti; Bernard Charbonnel; Andrew Cooper; Marília B. Gomes; Linong Ji; Paul Leigh; Antonio Nicolucci; Wolfgang Rathmann; Marina V. Shestakova; Afrah Siddiqui; Fengming Tang; Hirotaka Watada; Hungta Chen
Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea
Pharmacology Research & Perspectives 10(1) (2022)
Hyeri Yang; Eunmi Choi; Eunjun Park; Eonji Na; Soo Youn Chung; Bonggi Kim; Soon Young Han
Metabolic effects of empagliflozine
Diabetes Obesity Metabolic Syndrome(5) (2022)
Antonina Kedyk; Oleksandr Kutsyn
SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
Diabetologia 66(10) (2023)
Matthew Anson; Sizheng S. Zhao; Philip Austin; Gema H. Ibarburu; Rayaz A. Malik; Uazman Alam
Diabetes mellitus: an important risk factor for peripheral vascular disease
Expert Review of Cardiovascular Therapy 18(3) (2020)
Stefanos Giannopoulos; Ehrin J. Armstrong
Clinical Parameters Affecting the Therapeutic Efficacy of SGLT-2—Comparative Effectiveness and Safety of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes
Healthcare 10(7) (2022)
Irina Claudia Anton; Liliana Mititelu-Tartau; Eliza Gratiela Popa; Mihaela Poroch; Vladimir Poroch; Delia Reurean Pintilei; Gina Eosefina Botnariu